News on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
Pfizer expects its own trial of talazoparib for this new indication to wrap up in 2021, ideally recapitulating the positive results seen in this smaller group.
The data showed that population screening for BRCA mutations in Ashkenazi Jewish population doesn't diminish quality of life or cause psychological distress.
The drugmaker will present data from the Impower110 trial at an upcoming meeting and submit the data to regulatory authorities.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
Although the FDA has already approved the regimen in this indication after seeing its impact on progression-free survival, the latest data speaks to its impact on survival.
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
The researchers aimed to develop a test that could help clinicians determine whether a patient would respond to therapy, before the onset of treatment.
The cancer immunotherapy regimen and companion diagnostic test will be available in Europe for patients with triple-negative breast cancer who express PD-L1.
Researchers studied isolated CTCs along with real-world patient data and found that patients with blood-borne HER2 mutations may respond to anti-HER2 treatment.